WO2000006194A3 - Depletion of cells responsible for antibody-mediated graft rejection - Google Patents

Depletion of cells responsible for antibody-mediated graft rejection Download PDF

Info

Publication number
WO2000006194A3
WO2000006194A3 PCT/US1999/017190 US9917190W WO0006194A3 WO 2000006194 A3 WO2000006194 A3 WO 2000006194A3 US 9917190 W US9917190 W US 9917190W WO 0006194 A3 WO0006194 A3 WO 0006194A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
graft rejection
cause
xenograft
Prior art date
Application number
PCT/US1999/017190
Other languages
French (fr)
Other versions
WO2000006194A9 (en
WO2000006194A2 (en
Inventor
Arou Thall
Original Assignee
Biotransplant Inc
Arou Thall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotransplant Inc, Arou Thall filed Critical Biotransplant Inc
Priority to AU56688/99A priority Critical patent/AU5668899A/en
Publication of WO2000006194A2 publication Critical patent/WO2000006194A2/en
Publication of WO2000006194A3 publication Critical patent/WO2000006194A3/en
Publication of WO2000006194A9 publication Critical patent/WO2000006194A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides compositions, and methods of using said compositions, which are useful to reduce allogeneic or xenogeneic graft rejection. The invention provides methods and compositions for promoting in an animal of a first species a state of tolerance against Galα1,3Gal epitopes present on a xenograft from an animal of a second species, thereby preventing hyperacute rejection (HAR) of the xenograft. The methods and compositions according to the invention cause the elimination or anergy of specific lymphoid cells which are responsible for the production of xenoreactive natural antibodies (XNAs) which cause HAR of the xenograft. The invention also provides immunotoxin compositions and methods of using the same which are useful to reduce allogeneic or xenogeneic antibody-mediated graft rejection. The methods and compositions according to the invention cause the reduction or elimination of specific cells responsible for the production of antibodies that cause graft rejection.
PCT/US1999/017190 1997-02-05 1999-07-29 Depletion of cells responsible for antibody-mediated graft rejection WO2000006194A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU56688/99A AU5668899A (en) 1998-07-29 1999-07-29 Depletion of cells responsible for antibody-mediated graft rejection

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US79592597A 1997-02-05 1997-02-05
US13795698A 1998-02-05 1998-02-05
US12474498A 1998-07-29 1998-07-29
US09/124,744 1998-07-29

Publications (3)

Publication Number Publication Date
WO2000006194A2 WO2000006194A2 (en) 2000-02-10
WO2000006194A3 true WO2000006194A3 (en) 2000-08-24
WO2000006194A9 WO2000006194A9 (en) 2001-12-13

Family

ID=27383151

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/017190 WO2000006194A2 (en) 1997-02-05 1999-07-29 Depletion of cells responsible for antibody-mediated graft rejection

Country Status (1)

Country Link
WO (1) WO2000006194A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2496761C (en) 2002-08-21 2015-06-02 Revivicor, Inc. Porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase
EP1685148A2 (en) 2003-11-05 2006-08-02 University Of Pittsburgh Of The Commonwealth System Of Higher Education PORCINE ISOGLOBOSIDE 3 SYNTHASE PROTEIN, cDNA, GENOMIC ORGANIZATION, AND REGULATORY REGION
CA2559720A1 (en) 2004-03-17 2005-09-29 Revivicor, Inc. Tissue products derived from animals lacking any expression of functional alpha 1,3 galactosyltransferase
SI2567976T1 (en) 2005-03-23 2017-11-30 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
EP1748050A1 (en) * 2005-07-28 2007-01-31 Rijksuniversiteit Groningen Targeting-enhanced activation of galectins
GB0605395D0 (en) * 2006-03-16 2006-04-26 Norwegian Radium Hospital Res Anti-cancer therapy
SI2081595T1 (en) 2006-09-26 2019-10-30 Genmab As Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
LT2580243T (en) 2010-06-09 2020-01-27 Genmab A/S Antibodies against human cd38
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
HUE054529T2 (en) * 2014-03-11 2021-09-28 Molecular Templates Inc Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions capable of specifically binding cd38
MY192918A (en) 2014-09-09 2022-09-15 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
EP3227338A4 (en) 2014-12-04 2018-05-16 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
AU2016264725B2 (en) 2015-05-20 2021-05-27 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies
JP6816038B2 (en) 2015-06-22 2021-01-20 ヤンセン バイオテツク，インコーポレーテツド Combination therapy for hematological malignancies with anti-CD38 antibody and survivin inhibitor
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
MA53356B1 (en) 2015-11-03 2022-05-31 Janssen Biotech Inc Subcutaneous anti-cd38 antibody formulations and uses thereof
CA3079242A1 (en) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021799A1 (en) * 1993-03-16 1994-09-29 Austin Research Institute USE OF PORCINE GAL α(1,3) GALACTOSYL TRANSFERASE IN XENOGRAFT THERAPIES
WO1997011963A1 (en) * 1995-09-27 1997-04-03 The Austin Research Institute ANTI-GALα(1,3)GAL ANTIBODY BINDING PEPTIDES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994021799A1 (en) * 1993-03-16 1994-09-29 Austin Research Institute USE OF PORCINE GAL α(1,3) GALACTOSYL TRANSFERASE IN XENOGRAFT THERAPIES
WO1997011963A1 (en) * 1995-09-27 1997-04-03 The Austin Research Institute ANTI-GALα(1,3)GAL ANTIBODY BINDING PEPTIDES

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALEXEEV L.P. ET AL: "Pretreatment of kidney allografts with anti-CD5 immunotoxin: A new chance for high responder recipients.", TRANSPLANTATION PROCEEDINGS, (1997) 29/8 A (3605-3606)., XP000770271 *
GALILI U: "Interaction of the natural anti-gal antibody with alpha- galactosyl epitopes: a major obstacle for xenotransplantation in humans", IMMUNOLOGY TODAY,GB,ELSEVIER PUBLICATIONS, CAMBRIDGE, vol. 14, no. 10, 1 January 1993 (1993-01-01), pages 480 - 482, XP000672917, ISSN: 0167-5699 *
UCKUN F M ET AL: "Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation using autografts deplete of CD19 + B-cell precursors by an anti- CD19 pan-B-cell immunotoxin containing pokeweed antiviral protein.", BLOOD, (1992 JUN 15) 79 (12) 3369-79., XP000611308 *
VAN OOSTERHOUT, Y. V. J. M. ET AL: "Suitability of a cocktail of CD34 and CD7 ricin A - immunotoxins for in vivo treatment of acute graft -versus-host-disease.", BLOOD, (NOV. 15, 1997) VOL. 90, NO. 10 SUPPL. 1 PART 2, PP. 376B. MEETING INFO.: THIRTY-NINTH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY SAN DIEGO, CALIFORNIA, USA DECEMBER 5-9, 1997 THE AMERICAN SOCIETY OF HEMATOLOGY., XP000872341 *

Also Published As

Publication number Publication date
WO2000006194A9 (en) 2001-12-13
WO2000006194A2 (en) 2000-02-10

Similar Documents

Publication Publication Date Title
WO2000006194A3 (en) Depletion of cells responsible for antibody-mediated graft rejection
MY139523A (en) Ziprasidone composition and synthetic controls
WO2001077299A3 (en) A METHOD TO PREVENT GRAFT REJECTION USING TGF-β TO INDUCE T SUPPRESSOR CELLS
WO1997012035A3 (en) Transgenic animals for xenotransplantation with reduced antibody-mediated rejection
WO2001085207A3 (en) Modulation of antigen processing using phagocytic cells
EP1135415A4 (en) Humanized antibodies to gamma-interferon
WO2002081646A3 (en) Epitope sequences
IL210557A0 (en) Anti p-selectin glycoprotein ligand 1 (psgl-1) antibodies and antigen-binding fragments thereof
WO2002028867A3 (en) Ethers of 7-desmethylrapamycin for use in immunosuppression
WO1994001547A3 (en) A method for generation of antibodies to cell surface molecules
BG104236A (en) Transgenous mammals producing oligosaccharides in their milk
IL201889A (en) Therapeutic compositions for the treatment of immune related disorders comprising antibodies that specifically recognize the nk 1.1 antigen or the cd56 antigen expressed by nk t cells
WO2002047671A3 (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
WO2007067683A3 (en) Methods and compositions for expanding t regulatory cells
AU2238397A (en) Iscom or iscom-matrix comprising hydrophobic receptor molecules for antigenic substances
WO2002010337A3 (en) Method of cloning porcine animals
WO2003078604A3 (en) Tobacco rattle virus vectors and related compositions and methods
WO2006004588A3 (en) Immunodynamic complexes and methods for using and preparing such complexes
WO1998033528A3 (en) Induction of b cell tolerance
GB9825555D0 (en) Suppression of xenotransplant rejection
HK1016017A1 (en) Gonococcal anti-idiotypic antibodies and methods and compositions using them
WO1996040260A3 (en) Immunotoxins specific for cd80 and cd86 expressing cells
IL137668A0 (en) Method and device for extracting plant ingredients
EP2191839A3 (en) Immunogenic LHRH compositions and methods relating thereto
Zoglin et al. Chips ahoy.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 35-37, CLAIMS, REPLACED BY NEW PAGES 35-37; PAGES 1/16-16/16, DRAWINGS, REPLACED BY NEW PAGES1/16-16/16; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase